Literature DB >> 21570214

Biological optimization in volumetric modulated arc radiotherapy for prostate carcinoma.

Ivaylo B Mihaylov1, Mirek Fatyga, Karl Bzdusek, Kenneth Gardner, Eduardo G Moros.   

Abstract

PURPOSE: To investigate the potential benefits achievable with biological optimization for modulated volumetric arc (VMAT) treatments of prostate carcinoma. METHODS AND MATERIALS: Fifteen prostate patient plans were studied retrospectively. For each case, planning target volume, rectum, and bladder were considered. Three optimization schemes were used: dose-volume histogram (DVH) based, generalized equivalent uniform dose (gEUD) based, and mixed DVH/gEUD based. For each scheme, a single or dual 6-MV, 356° VMAT arc was used. The plans were optimized with Pinnacle(3) (v. 9.0 beta) treatment planning system. For each patient, the optimized dose distributions were normalized to deliver the same prescription dose. The quality of the plans was evaluated by dose indices (DIs) and gEUDs for rectum and bladder. The tallied DIs were D(1%), D(15%), D(25%), and D(40%), and the tallied gEUDs were for a values of 1 and 6. Statistical tests were used to quantify the magnitude and the significance of the observed differences. Monitor units and treatment times for each optimization scheme were also assessed.
RESULTS: All optimization schemes generated clinically acceptable plans. The statistical tests indicated that biological optimization yielded increased organs-at-risk sparing, ranging from ~1% to more than ~27% depending on the tallied DI, gEUD, and anatomical structure. The increased sparing was at the expense of longer treatment times and increased number of monitor units.
CONCLUSIONS: Biological optimization can significantly increase the organs-at-risk sparing in VMAT optimization for prostate carcinoma. In some particular cases, however, the DVH-based optimization resulted in superior treatment plans.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21570214     DOI: 10.1016/j.ijrobp.2010.06.020

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  7 in total

1.  Risk-optimized proton therapy to minimize radiogenic second cancers.

Authors:  Laura A Rechner; John G Eley; Rebecca M Howell; Rui Zhang; Dragan Mirkovic; Wayne D Newhauser
Journal:  Phys Med Biol       Date:  2015-04-28       Impact factor: 3.609

2.  New approach in lung cancer radiotherapy offers better normal tissue sparing.

Authors:  Ivaylo B Mihaylov
Journal:  Radiother Oncol       Date:  2016-09-28       Impact factor: 6.280

3.  Automated inverse optimization facilitates lower doses to normal tissue in pancreatic stereotactic body radiotherapy.

Authors:  Ivaylo B Mihaylov; Eric A Mellon; Raphael Yechieli; Lorraine Portelance
Journal:  PLoS One       Date:  2018-01-19       Impact factor: 3.240

4.  Integral Dose-Based Inverse Optimization May Reduce Side Effects in Radiotherapy of Prostate Carcinoma.

Authors:  Ivaylo B Mihaylov
Journal:  Front Oncol       Date:  2017-03-01       Impact factor: 6.244

5.  Risk-adaptive volumetric modulated arc therapy using biological objective functions for subvolume boosting in radiotherapy.

Authors:  Nicholas Hardcastle; Wolfgang A Tome
Journal:  Comput Math Methods Med       Date:  2012-06-27       Impact factor: 2.238

6.  Efficiency of biological versus physical optimization for single-arc VMAT for prostate and head and neck cases.

Authors:  Vadzim Pyshniak; Irina Fotina; Alena Zverava; Stanislau Siamkouski; Elena Zayats; Georgy Kopanitsa; Dzmitry Okuntsau
Journal:  J Appl Clin Med Phys       Date:  2014-07-08       Impact factor: 2.102

7.  Biological optimization for mediastinal lymphoma radiotherapy - a preliminary study.

Authors:  Laura Ann Rechner; Arezoo Modiri; Line Bjerregaard Stick; Maja V Maraldo; Marianne C Aznar; Stephanie R Rice; Amit Sawant; Søren M Bentzen; Ivan Richter Vogelius; Lena Specht
Journal:  Acta Oncol       Date:  2020-03-27       Impact factor: 4.089

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.